- Home
- KLRS vs TPST Comparison
KLRS vs TPST Comparison
Compare KLRS & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- TPST
- Stock Information
- Founded
- KLRS 2019
- TPST 2011
- Country
- KLRS United States
- TPST United States
- Employees
- KLRS N/A
- TPST N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- KLRS Health Care
- TPST Health Care
- Exchange
- KLRS Nasdaq
- TPST Nasdaq
- Market Cap
- KLRS 46.0M
- TPST 45.5M
- IPO Year
- KLRS N/A
- TPST N/A
- Fundamental
- Price
- KLRS $4.39
- TPST $10.01
- Analyst Decision
- KLRS Strong Buy
- TPST Hold
- Analyst Count
- KLRS 2
- TPST 3
- Target Price
- KLRS $23.00
- TPST $30.00
- AVG Volume (30 Days)
- KLRS 728.6K
- TPST 55.3K
- Earning Date
- KLRS 11-15-2025
- TPST 11-11-2025
- Dividend Yield
- KLRS N/A
- TPST N/A
- EPS Growth
- KLRS N/A
- TPST N/A
- EPS
- KLRS N/A
- TPST N/A
- Revenue
- KLRS N/A
- TPST N/A
- Revenue This Year
- KLRS N/A
- TPST N/A
- Revenue Next Year
- KLRS N/A
- TPST N/A
- P/E Ratio
- KLRS N/A
- TPST N/A
- Revenue Growth
- KLRS N/A
- TPST N/A
- 52 Week Low
- KLRS $2.14
- TPST $5.35
- 52 Week High
- KLRS $24.15
- TPST $20.67
- Technical
- Relative Strength Index (RSI)
- KLRS 58.92
- TPST 52.17
- Support Level
- KLRS $3.49
- TPST $9.57
- Resistance Level
- KLRS $5.30
- TPST $11.02
- Average True Range (ATR)
- KLRS 0.77
- TPST 0.58
- MACD
- KLRS -0.01
- TPST -0.19
- Stochastic Oscillator
- KLRS 23.97
- TPST 30.45
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.